USE OF ISOINDOLES FOR THE TREATMENT OF NEUROBEHAVIORAL DISORDERS
The present invention generally relates to the use of drugs for the treatment of a neurobehavioral disorder associated with dysfunction of the trimonoamine modulating system (TMMS). More specifically, the invention describes methods for the treatment of a neurobehavioral disorder and/or treatment or prevention of symptoms of a neurobehavioral disorder by administering suitable Isoindole derivatives alone or in combination with other agents so as to provide relatively equal inhibitory effect on serotonin, dopamine and norepinephrine transporters.
1 . A prodrug or a pharmaceutically acceptable salt thereof, comprising mazindol conjugated to a promoiety selected from the group consisting of a bile acid, a vitamin, an essential fatty acid, a choline, or a derivative or an analogue thereof.
2 . The prodrug of claim 1 , wherein the promoiety is a bile acid.
3 . The prodrug of claim 1 , wherein the promoiety is a vitamin.
4 . The prodrug of claim 1 , wherein the promoiety is a choline.
5 . The prodrug of claim 1 , wherein the promoiety is an essential fatty acid.
6 . The prodrug of claim 5 , wherein the essential fatty acid is N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo-yl)-L-glutamic acid (folic acid).
7 . The prodrug of claim 6 , wherein the folic acid is conjugated to mazindol by the formation of an ester linkage.
8 . The prodrug of claim 7 is 2-(4-((2-amino-4-oxo-1,4-dihydropteridin-6-yl)methylamino)benzamido)-5-(5-(4-chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-yloxy)-5-oxopentanoic acid.